Wedbush Securities’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $853K | Sell |
13,588
-1
| -0% | -$70 | 0.02% | 507 |
|
|
2025
Q4 | $902K | Buy |
13,589
+52
| +0.4% | +$3.36K | 0.03% | 475 |
|
|
2025
Q3 | $911K | Buy |
13,537
+327
| +2% | +$25.9K | 0.03% | 457 |
|
|
2025
Q2 | $1.15M | Buy |
13,210
+42
| +0.3% | +$3.29K | 0.04% | 374 |
|
|
2025
Q1 | $899K | Buy |
13,168
+157
| +1% | +$12.8K | 0.03% | 418 |
|
|
2024
Q4 | $1.01M | Sell |
13,011
-3
| -0% | -$222 | 0.04% | 375 |
|
|
2024
Q3 | $872K | Sell |
13,014
-213
| -2% | -$17.5K | 0.03% | 410 |
|
|
2024
Q2 | $1.5M | Sell |
13,227
-230
| -2% | -$29.1K | 0.05% | 261 |
|
|
2024
Q1 | $1.87M | Buy |
13,457
+157
| +1% | +$19.7K | 0.07% | 227 |
|
|
2023
Q4 | $1.65M | Sell |
13,300
-338
| -2% | -$34.5K | 0.07% | 204 |
|
|
2023
Q3 | $1.27M | Sell |
13,638
-318
| -2% | -$35.8K | 0.06% | 245 |
|
|
2023
Q2 | $1.79M | Sell |
13,956
-641
| -4% | -$77.5K | 0.09% | 179 |
|
|
2023
Q1 | $1.7M | Sell |
14,597
-321
| -2% | -$35.9K | 0.08% | 179 |
|
|
2022
Q4 | $1.69M | Buy |
14,918
+66
| +0.4% | +$7.25K | 0.09% | 174 |
|
|
2022
Q3 | $1.2M | Sell |
14,852
-205
| -1% | -$17.4K | 0.07% | 240 |
|
|
2022
Q2 | $1.12M | Buy |
15,057
+205
| +1% | +$18.7K | 0.06% | 263 |
|
|
2022
Q1 | $1.9M | Buy |
14,852
+260
| +2% | +$28.4K | 0.09% | 189 |
|
|
2021
Q4 | $1.96M | Sell |
14,592
-68
| -0.5% | -$9.77K | 0.08% | 191 |
|
|
2021
Q3 | $2M | Buy |
14,660
+204
| +1% | +$25.7K | 0.1% | 183 |
|
|
2021
Q2 | $1.54M | Buy |
14,456
+816
| +6% | +$78.4K | 0.07% | 250 |
|
|
2021
Q1 | $1.23M | Buy |
13,640
+32
| +0.2% | +$3K | 0.07% | 273 |
|
|
2020
Q4 | $1.26M | Sell |
13,608
-560
| -4% | -$50K | 0.11% | 195 |
|
|
2020
Q3 | $1.46M | Sell |
14,168
-648
| -4% | -$67.7K | 0.14% | 153 |
|
|
2020
Q2 | $1.5M | Buy |
14,816
+1,308
| +10% | +$117K | 0.14% | 145 |
|
|
2020
Q1 | $909K | Buy |
13,508
+452
| +3% | +$28.1K | 0.11% | 196 |
|
|
2019
Q4 | $714K | Sell |
13,056
-56
| -0.4% | -$2.66K | 0.06% | 343 |
|
|
2019
Q3 | $489K | Buy |
13,112
+680
| +5% | +$26.4K | 0.05% | 459 |
|
|
2019
Q2 | $466K | Buy |
12,432
+520
| +4% | +$16.3K | 0.05% | 462 |
|
|
2019
Q1 | $355K | Sell |
11,912
-28
| -0.2% | -$984 | 0.04% | 541 |
|
|
2018
Q4 | $358K | Sell |
11,940
-2,136
| -15% | -$67.8K | 0.05% | 471 |
|
|
2018
Q3 | $503K | Sell |
14,076
-80
| -0.6% | -$2.48K | 0.06% | 391 |
|
|
2018
Q2 | $336K | Buy |
14,156
+336
| +2% | +$7.12K | 0.04% | 518 |
|
|
2018
Q1 | $256K | Sell |
13,820
-8,536
| -38% | -$126K | 0.03% | 590 |
|
|
2017
Q4 | $321K | Buy |
22,356
+4,356
| +24% | +$56.6K | 0.04% | 520 |
|
|
2017
Q3 | $220K | Buy |
18,000
+1,200
| +7% | +$21.2K | 0.03% | 672 |
|
|
2017
Q2 | $307K | Buy |
16,800
+800
| +5% | +$14.8K | 0.04% | 533 |
|
|
2017
Q1 | $339K | Buy |
+16,000
| New | +$312K | 0.05% | 489 |
|
|
2016
Q4 | – | Sell |
-12,200
| Closed | -$267K | – | 834 |
|
|
2016
Q3 | $267K | Hold |
12,200
| – | – | 0.04% | 559 |
|
|
2016
Q2 | $242K | Sell |
12,200
-1,600
| -12% | -$27.2K | 0.04% | 553 |
|
|
2016
Q1 | $234K | Sell |
13,800
-2,000
| -13% | -$33.4K | 0.04% | 530 |
|
|
2015
Q4 | $324K | Hold |
15,800
| – | – | 0.06% | 379 |
|
|
2015
Q3 | $339K | Buy |
15,800
+800
| +5% | +$17.8K | 0.07% | 328 |
|
|
2015
Q2 | $300K | Buy |
15,000
+1,000
| +7% | +$17.6K | 0.06% | 432 |
|
|
2015
Q1 | $218K | Buy |
+14,000
| New | +$212K | 0.04% | 549 |
|
Other funds holding DXCM
VCM
VPM
Wedbush Securities's DXCM Position: Q1 2026 in Review
Wedbush Securities reduced its DexCom (DXCM) stake by 0.01% in Q1 2026, selling an estimated $70 and leaving 13,588 shares worth $853K. The position accounts for 0.02% of the portfolio, ranked #507.
Wedbush Securities first reported a position in DXCM in Q1 2015 and has held it in 44 quarters since. The position peaked at $2M in Q3 2021. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Wedbush Securities held 13,588 shares of DexCom worth $853K as of Q1 2026.
- Wedbush Securities sold 1 DexCom share in Q1 2026, an estimated $70.
- DexCom made up 0.02% of Wedbush Securities's portfolio in Q1 2026, its #507 holding.
- Wedbush Securities first reported a position in DexCom in Q1 2015 and has held it in 44 quarters since.
- Wedbush Securities's DexCom position peaked at $2M in Q3 2021.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.